Wrongful Death Lawsuit Alleges Androgel Not Safe For Human Use

A wrongful death lawsuit filed against AbbVie alleges that the side effects of AndroGel and other testosterone replacement therapy make the drugs unfit for human use. 

Mary Alfimow filed the complaint (PDF) in the U.S. District Court for the Eastern District of Pennsylvania on January 20, on behalf of herself and her deceased husband, Valerik Alfimow.

According to allegations raised in the wrongful death lawsuit, which was filed against AbbVie Inc. and Abbott Laboratories, the makers of Androgel, Alfimow died of cardiac arrest due to his use of the low testosterone gel.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

Alfimow began using AndroGel in August 2010, after his doctor diagnosed him with hypogonadism. However, the lawsuit notes neither he nor his doctor were informed that the testosterone gel could increase the risk of heart attack, stroke, pulmonary embolism, deep vein thrombosis or death.

On January 20, 2014, Alfimow suffered cardiac arrest and died, which the lawsuit claims was the result of his use of AndroGel.

The case is one of about 3,500 testosterone drug lawsuits filed in U.S. District Courts nationwide, which have been consolidated for pretrial proceedings as part of a federal multidistrict litigation (MDL). The cases are all centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois, for coordinated discovery and a series of early “bellwether” trials expected to begin next year.

Testosterone Health Risks

This recent lawsuit accuses AbbVie, and its former owner, Abbott Laboratories, of aggressively marketing AndroGel to men who did not need the medication, while failing to conduct proper studies to ensure the testosterone gel was safe.

“The marketing program sought to create the image and belief by consumers and physicians that low testosterone affected a large number of men in the United States and that the use of AndroGel is safe for human use, even though Defendants knew these statements to be false, and even though Defendants had no reasonable grounds to believe them to be true,” the lawsuit states. “There have been a number of studies suggesting that testosterone use in men increases the risk of heart attacks and strokes.”

In addition to Androgel lawsuits, similar allegations have been raised in Axiron lawsuits, Testim lawsuits and other claims over popular testosterone drugs that have been aggressively marketed in recent years.

Litigation over the testosterone blood clot risks emerged in November 2013, after a study published in the Journal of the American Medical Association (JAMA) found that certain men who began taking testosterone drugs following coronary angiography may be more likely to suffer cardiovascular events.

That study was followed by additional research published in the medical journal PLoSOne in January 2014, which found that side effects of testosterone drugs may double the risk of heart attacks for men over the age of 65, regardless of their prior health condition, as well as double the risk for younger men with a prior history of heart disease.

In January 2015, another study published in the medical journal Pharmacotherapy found that first time testosterone users may be 40% more likely to have a heart attack when compared to men who did not use the drugs.

The FDA announced a warning label update for testosterone therapy in March 2015, indicating that new information would be added about the evidence of a link between testosterone drugs and heart problems. In addition, the agency encouraged doctors not to prescribe testosterone drugs for so-called “life-style” reasons, such as addressing decreased energy levels or sexual drive experienced by most men as they get older.

As part of the MDL proceedings before Judge Kennelly, a small group of Androgel lawsuits are currently being prepared for early trial dates. Known as bellwether cases, these trials are designed to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout a number of cases.

Following a series of bellwether trials in the MDL, if testosterone drug settlements are not reached by AbbVie and other manufacturers of low testosterone drugs, a second series of bellwether trials are expected to begin involving the use of other drugs.


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Suboxone Settlements Failed to Compensate Users Left With Tooth Decay or Tooth loss
Suboxone Settlements Failed to Compensate Users Left With Tooth Decay or Tooth loss (Posted today)

Although Suboxone settlements have been paid to resolve antitrust violations, users who suffered damages due to tooth decay from Suboxone film must pursue individual product liability lawsuits

Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024
Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024 (Posted yesterday)

With thousands of Bard hernia mesh lawsuits pending in the federal court system, a fourth bellwether trial will be held in the spring, involving allegations that defects with Bard 3DMax caused painful and permanent injuries.